Source: International Congress 2014 – COPD - from biomarkers to novel therapeutic opportunities
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. T. E. Kuo, K. Lau, G. Hamilton, E. Dai, P. Leong, P. Bardin (Melbourne, Australia). A pilot study of CPAP therapy for excessive dynamic airway collapse during acute exacerbation of COPD. Eur Respir J 2014; 44: Suppl. 58, 3401

Member's Comments

No comment yet.

Related content which might interest you: Frequency of COPD exacerbations and severity of COPD Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 COPD on anti-GERD therapy remains at higher risk for severe exacerbation Source: International Congress 2014 – COPD exacerbations Year: 2014 Importance of the initial behaviour of patients in avoiding late recovery from COPD exacerbations Source: Annual Congress 2013 –COPD: acute exacerbations and others Year: 2013 Symptom profile of exacerbations in earlier and later COPD Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes Year: 2013 Recording and response to hyperglycaemia in patients presenting with infective exacerbations of COPD Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 The relationship between 24-hour symptoms and COPD exacerbations: Results from ASSESS Source: International Congress 2014 – COPD exacerbations Year: 2014 Mukoregulatory drugs in treating COPD Source: International Congress 2014 – Predictors Year: 2014 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Outcomes of COPD exacerbations - a report from the ERS COPD audit in Austria Source: Annual Congress 2013 –COPD: acute exacerbations and others Year: 2013 The bronchitic phenotype is associated with frequent exacerbations in COPD irrespective of chronic bacterial airway infection Source: Annual Congress 2013 –Guidelines and exacerbations Year: 2013 Impact of frequent exacerbations in patients with COPD Source: International Congress 2014 – Clinical presentations Year: 2014 Clinical characteristics of patients with clinically-diagnosed COPD exacerbations but without concomitant airflow limitation Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015 Severity of airflow obstruction and multicomponent disease staging of COPD in the real-world primary care in Greece: The AEOLUS study Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Do inhaled corticosteroids reduce the frequent exacerbator phenotype in COPD - A little help by a multicenter survey Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Eosinophilic airway inflammation as a complication of COPD, and the usefulness of ICS on these cases Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 A self-treatment programme in patients with COPD: Effectiveness for the reduction of severe exacerbations Source: International Congress 2015 – Latest insights into chronic care Year: 2015 Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability Source: International Congress 2014 – Markers Year: 2014 Can roflumilast improve clinical outcomes in moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis Source: International Congress 2016 – COPD diagnosis and management Year: 2016 Exacerbations in patients with chronic obstructive lung disease (COPD) and concomitant asthma Source: International Congress 2014 – Asthma or COPD: comorbid condition or a poorly understood single disease? Year: 2014